149 results on '"Bil J"'
Search Results
2. HIV testing history and access to treatment among migrants living with HIV in Europe
- Author
-
Fakoya, Ibidun, Arco, Débora Álvarez?Del, Monge, Susana, Copas, Andrew J., Gennotte, Anne?Francoise, Volny?Anne, Alain, Wengenroth, Claudia, Touloumi, Giota, Prins, Maria, Barros, Henrique, Darling, Katharine Ea, Prestileo, Tullio, Del Amo, Julia, Burns, Fiona M., Aerssens, A, Aguado, M, Alimi, B, Anagnostou, O, Anderson, J, Antoniadou, A, Arando, M, Barberà, Mj, Barthélemy, A, Belda?Ibáñez, J, Bertisch, B, Bil, J, Blanco, Jr, Block, K, Boesecke, C, Boura, M, Burgos, J, Cabo, J, Calabuig, E, Campbell, L, Cardoso, O, Claudia, W, Clumeck, N, Colucci, A, Corrao, S, Cuellar, S, Cunha, J, Daikos, G, Darling, K, Romero, J, Dellot, P, Domingo, P, Dronda, F, Ebeling, F, Engelhardt, A, Engler, B, Farrell, J, Fehr, J, Feijó, M, Fernández, E, García, E Fernández, Fernandez, T, Fortes, Al, Fox, J, De Olalla, P Garcia, García, F, Gargalianos?Kakolyris, P, Germano, I, Gilleran, G, Gilson, R, Goepel, S, Gogos, Ha, Sirvent, Jl Gómez, Gountas, I, Gregg, A, Gutiérrez, F, Gutierrez, Mm, Hermans, I, Iribarren, Ja, Knobel, H, Koulai, L, Kourkounti, S, La Morté, C, Lecompte, T, Ledergerber, B, Leonidou, L, Ligero, Mc, Lindergard, G, Lino, S, Lopes, Mj, Lirola, A Lopez, Louhenapessy, M, Lourida, G, Luzi, Am, Maltez, F, Manirankunda, L, Martín?Pérez, A, Martins, L, Masía, M, Mateu, Mg, Meireles, P, Mendes, A, Metallidis, S, Mguni, S, Milinkovic, A, Miró, Jm, Mohrmann, K, Montero, M, Mouhebati, T, Moutschen, M, Müller, M, Murphy, C, Nöstlinger, C, Ocaña, I, Okumu?Fransche, S, Onwuchekwa, G, Ospina, Je, Otiko, D, Pacheco, P, Palacios, R, Paparizos, V, Papastamopoulos, V, Paredes, V, Patel, N, Pellicer, T, Peña, A, Petrosillo, N, Pinheiro, A, Poças, J, Portillo, A, Post, F, Prestileo, F, Prins, P, Protopapas, K, Psichogiou, M, Pulido, F, Rebollo, J, Ribeirinho, A, Río, I, Robau, M, Rockstroh, Jk, Rodrigues, E, Rodríguez, M, Sajani, C, Salavert, M, Salman, R, Sanz, N, Schuettfort, G, Schüttfort, G, Zander, C Schwarze?, Serrão, R, Silva, D, Silva, V, Silverio, P, Skoutelis, A, Staehelin, C, Stephan, C, Stretton, C, Styles, F, Sutre, Af, Taylor, S, Teixeira, B, Thierfelder, C, Tsachouridou, O, Tudor, K, Valadas, E, Frankenhuijsen, M, Vázquez, M, Arribas, M Velasco, Vera, M, Vinciana, P, Voudouri, N, Wasmuth, Jc, Wilkins, E, Young, L, Yurdakul, S, Espinosa, T Zafra, Zuilhof, W, and Zuure, F more...
- Subjects
HIV testing -- Surveys ,Immigrants -- Surveys -- Care and treatment ,HIV infection -- Surveys -- Diagnosis -- Care and treatment ,Health - Abstract
: Introduction: Migrants are overrepresented in the European HIV epidemic. We aimed to understand the barriers and facilitators to HIV testing and current treatment and healthcare needs of migrants living with HIV in Europe. Methods: A cross‐sectional study was conducted in 57 HIV clinics in nine countries (Belgium, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Switzerland and United Kingdom), July 2013 to July 2015. HIV‐positive patients were eligible for inclusion if they were as follows: 18 years or older; foreign‐born residents and diagnosed within five years of recruitment. Questionnaires were completed electronically in one of 15 languages and linked to clinical records. Primary outcomes were access to primary care and previous negative HIV test. Data were analysed using random effects logistic regression. Outcomes of interest are presented for women, heterosexual men and gay/bisexual men. Results: A total of 2093 respondents (658 women, 446 heterosexual men and 989 gay/bisexual men) were included. The prevalence of a previous negative HIV test was 46.7%, 43.4% and 82.0% for women, heterosexual and gay/bisexual men respectively. In multivariable analysis previous testing was positively associated with: receipt of post‐migration antenatal care among women, permanent residency among heterosexual men and identifying as gay rather than bisexual among gay/bisexual men. Access to primary care was found to be high (>83%) in all groups and was strongly associated with country of residence. Late diagnosis was common for women and heterosexual men (60.8% and 67.1%, respectively) despite utilization of health services prior to diagnosis. Across all groups almost three‐quarters of people on antiretrovirals had an HIV viral load Conclusions: Migrants access healthcare in Europe and while many migrants had previously tested for HIV, that they went on to test positive at a later date suggests that opportunities for HIV prevention are being missed. Expansion of testing beyond sexual health and antenatal settings is still required and testing opportunities should be linked with combination prevention measures such as access to PrEP and treatment as prevention., Introduction The HIV epidemic in Europe is characterized by a disproportionate number of infections among migrants. Although foreign citizens only made up 7% of the population of the European Union [...] more...
- Published
- 2018
- Full Text
- View/download PDF
Catalog
3. Duration of dual antiplatelet therapy and long-term outcomes following drug-eluting balloon or drug-eluting stents for treatment of in-stent restenosis (DAPT-Dragon Registry)
- Author
-
Januszek, R, primary, Bil, J, additional, Figatowski, T, additional, Tomasiewicz, B, additional, Desperak, P, additional, Niezgoda, P, additional, Reczuch, K, additional, Kubica, J, additional, Gil, R J, additional, Bartus, S, additional, Gasior, M, additional, Witkowski, A, additional, Jaguszewski, M, additional, Wojakowski, W, additional, and Wanha, W, additional more...
- Published
- 2021
- Full Text
- View/download PDF
4. Regulation of CD20 levels in B-cell tumors by SRC family kinases: SW05.S24–9
- Author
-
Bojarczuk, K., Winiarska, M., Bil, J., Wanczyk, M., Dwojak, M., Nowis, D., Miazek, N., Zapala, P., Dabrowska-Iwanicka, A., Juszczynski, P., and Golab, J.
- Published
- 2013
5. Predictors of long-term outcomes of coronary bifurcation stenting: 6-year results from international, randomized POLBOS I and POLBOS II clinical trials
- Author
-
Gil, R.J, primary, Kern, A, additional, Inigo Garcia, L.A, additional, Formuszewicz, R.J, additional, Dobrzycki, S, additional, Vassilev, D, additional, and Bil, J, additional
- Published
- 2020
- Full Text
- View/download PDF
6. EP02.13: Ultrasonographic placental changes in women with gestational diabetes: a pilot study
- Author
-
Schiffer, V., primary, Groen, M., additional, Bil, J., additional, Spaanderman, M., additional, and Al Nasiry, S., additional
- Published
- 2019
- Full Text
- View/download PDF
7. HIV testing history and access to treatment among migrants living with HIV in Europe
- Author
-
Fakoya, I. Álvarez-Del Arco, D. Monge, S. Copas, A.J. Gennotte, A.-F. Volny-Anne, A. Wengenroth, C. Touloumi, G. Prins, M. Barros, H. Darling, K.E.A. Prestileo, T. Del Amo, J. Burns, F.M. Aerssens, A. Aguado, M. Alimi, B. Anagnostou, O. Anderson, J. Antoniadou, A. Arando, M. Barberà, M.J. Barthélemy, A. Belda-Ibáñez, J. Bertisch, B. Bil, J. Blanco, J.R. Block, K. Boesecke, C. Boura, M. Burgos, J. Cabo, J. Calabuig, E. Campbell, L. Cardoso, O. Claudia, W. Clumeck, N. Colucci, A. Corrao, S. Cuellar, S. Cunha, J. Daikos, G. Darling, K. del Romero, J. Dellot, P. Domingo, P. Dronda, F. Ebeling, F. Engelhardt, A. Engler, B. Farrell, J. Fehr, J. Feijó, M. Fernández, E. Fernández García, E. Fernandez, T. Fortes, A.L. Fox, J. Garcia de Olalla, P. García, F. Gargalianos-Kakolyris, P. Germano, I. Gilleran, G. Gilson, R. Goepel, S. Gogos, H.A. Gómez Sirvent, J.L. Gountas, I. Gregg, A. Gutiérrez, F. Gutierrez, M.M. Hermans, I. Iribarren, J.A. Knobel, H. Koulai, L. Kourkounti, S. La Morté, C. LeCompte, T. Ledergerber, B. Leonidou, L. Ligero, M.C. Lindergard, G. Lino, S. Lopes, M.J. Lopez Lirola, A. Louhenapessy, M. Lourida, G. Luzi, A.M. Maltez, F. Manirankunda, L. Martín-Pérez, A. Martins, L. Masía, M. Mateu, M.G. Meireles, P. Mendes, A. Metallidis, S. Mguni, S. Milinkovic, A. Miró, J.M. Mohrmann, K. Montero, M. Mouhebati, T. Moutschen, M. Müller, M. Murphy, C. Nöstlinger, C. Ocaña, I. Okumu-Fransche, S. Onwuchekwa, G. Ospina, J.E. Otiko, D. Pacheco, P. Palacios, R. Paparizos, V. Papastamopoulos, V. Paredes, V. Patel, N. Pellicer, T. Peña, A. Petrosillo, N. Pinheiro, A. Poças, J. Portillo, A. Post, F. Prestileo, F. Prins, P. Protopapas, K. Psichogiou, M. Pulido, F. Rebollo, J. Ribeirinho, A. Río, I. Robau, M. Rockstroh, J.K. Rodrigues, E. Rodríguez, M. Sajani, C. Salavert, M. Salman, R. Sanz, N. Schuettfort, G. Schüttfort, G. Schwarze- Zander, C. Serrão, R. Silva, D. Silva, V. Silverio, P. Skoutelis, A. Staehelin, C. Stephan, C. Stretton, C. Styles, F. Sutre, A.F. Taylor, S. Teixeira, B. Thierfelder, C. Tsachouridou, O. Tudor, K. Valadas, E. van Frankenhuijsen, M. Vázquez, M. Velasco Arribas, M. Vera, M. Vinciana, P. Voudouri, N. Wasmuth, J.C. Wilkins, E. Young, L. Yurdakul, S. Zafra Espinosa, T. Zuilhof, W. Zuure, F. the aMASE Study Team more...
- Subjects
virus diseases - Abstract
Introduction: Migrants are overrepresented in the European HIV epidemic. We aimed to understand the barriers and facilitators to HIV testing and current treatment and healthcare needs of migrants living with HIV in Europe. Methods: A cross-sectional study was conducted in 57 HIV clinics in nine countries (Belgium, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Switzerland and United Kingdom), July 2013 to July 2015. HIV-positive patients were eligible for inclusion if they were as follows: 18 years or older; foreign-born residents and diagnosed within five years of recruitment. Questionnaires were completed electronically in one of 15 languages and linked to clinical records. Primary outcomes were access to primary care and previous negative HIV test. Data were analysed using random effects logistic regression. Outcomes of interest are presented for women, heterosexual men and gay/bisexual men. Results: A total of 2093 respondents (658 women, 446 heterosexual men and 989 gay/bisexual men) were included. The prevalence of a previous negative HIV test was 46.7%, 43.4% and 82.0% for women, heterosexual and gay/bisexual men respectively. In multivariable analysis previous testing was positively associated with: receipt of post-migration antenatal care among women, permanent residency among heterosexual men and identifying as gay rather than bisexual among gay/bisexual men. Access to primary care was found to be high (>83%) in all groups and was strongly associated with country of residence. Late diagnosis was common for women and heterosexual men (60.8% and 67.1%, respectively) despite utilization of health services prior to diagnosis. Across all groups almost three-quarters of people on antiretrovirals had an HIV viral load more...
- Published
- 2018
8. P3574Distal left main trifurcation treatment with dedicated bifurcation stents: subgroup analysis from randomized clinical trials POLBOS I and POLBOS II
- Author
-
Gil, R J, primary, Bil, J, additional, Kern, A, additional, Inigo-Garcia, L A, additional, Formuszewicz, R, additional, Dobrzycki, S, additional, and Vassilev, D, additional
- Published
- 2018
- Full Text
- View/download PDF
9. P4648Efficacy of provocative acetylcholine test in patients with MINOCA - 5-year follow-up from AChPOL Registry
- Author
-
Bil, J, primary, Mozenska, O, additional, Pawlowski, T, additional, and Gil, R J, additional
- Published
- 2018
- Full Text
- View/download PDF
10. P5526First-in-man study of the dedicated bifurcation cobalt-chromium sirolimus-eluting stent: 9-month interim results
- Author
-
Gil, R J, primary, Bil, J, additional, Kern, A, additional, and Pawlowski, T, additional
- Published
- 2018
- Full Text
- View/download PDF
11. High levels of postmigration HIV acquisition within nine European countries
- Author
-
Alvarez-Del Arco, D. Fakoya, I. Thomadakis, C. Pantazis, N. Touloumi, G. Gennotte, A.-F. Zuure, F. Barros, H. Staehelin, C. Göpel, S. Boesecke, C. Prestileo, T. Volny-Anne, A. Burns, F. Del Amo, J. Aerssens, A. Aguado, M. Alimi, B. Álvarez-Del Arco, D. Anagnostou, O. Anderson, J. Antoniadou, A. Arando, M. Barberà, M.J. Barthélemy, A. Belda-Ibáñez, J. Bertisch, B. Bil, J. Blanco, J.R. Block, K. Boesecke, C. Boura, M. Burgos, J. Burns, F.M. Cabo, J. Calabuig, E. Campbell, L. Cardoso, O. Claudia, W. Clumeck, N. Colucci, A. Corrao, S. Cuellar, S. Cunha, J. Daikos, G. Darling, K. Del Amo, J. Del Romero, J. Dellot, P. Dixneuf, M. Domingo, P. Dronda, F. Ebeling, F. Engelhardt, A. Engler, B. Fakoya, I. Farrell, J. Fehr, J. Feijó, M. Fernández, E. Fernández García, E. Fernandez, T. Fortes, A.L. Fox, J. Garcia De Olalla, P. García, F. Gargalianos-Kakolyris, P. Gennotte, A.F. Germano, I. Gilleran, G. Gilson, R. Goepel, S. Gogos, H.A. Gómez Sirvent, J.L. Gountas, I. Gregg, A. Gutiérrez, F. Gutierrez, M.M. Hermans, I. Iribarren, J.A. Knobel, H. Koulai, L. Kourkounti, S. La Morté, C. LeCompte, T. Ledergerber, B. Leonidou, L. Ligero, M.C. Lindergard, G. Lino, S. Lopes, M.J. Lopez Lirola, A. Louhenapessy, M. Lourida, G. Luzi, A.M. Maltez, F. Manirankunda, L. Martín-Pérez, A. Martins, L. Masía, M. Mateu, M.G. Meireles, P. Mendes, A. Metallidis, S. Mguni, S. Milinkovic, A. Miró, J.M. Mohrmann, K. Monge, S. Montero, M. Mouhebati, T. Moutschen, M. Müller, M. Murphy, C. Nöstlinger, C. Ocaña, I. Okumu-Fransche, S. Onwuchekwa, G. Ospina, J.E. Otiko, D. Pacheco, P. Palacios, R. Paparizos, V. Papastamopoulos, V. Paredes, V. Patel, N. Pellicer, T. Peña, A. Petrosillo, N. Pinheiro, A. Poças, J. Portillo, A. Post, F. Prestileo, F. Prestileo, T. Prins, M. Prins, P. Protopapas, K. Psichogiou, M. Pulido, F. Rebollo, J. Ribeirinho, A. Río, I. Robau, M. Rockstroh, J.K. Rodrigues, E. Rodríguez, M. Sajani, C. Salavert, M. Salman, R. Sanz, N. Schuettfort, G. Schüttfort, G. Schwarze-Zander, C. Serrão, R. Silva, D. Silva, V. Silverio, P. Skoutelis, A. Staehelin, C. Stephan, C. Stretton, C. Styles, F. Sutre, A.F. Taylor, S. Teixeira, B. Thierfelder, C. Touloumi, G. Tsachouridou, O. Tudor, K. Valadas, E. Van Frankenhuijsen, M. Vázquez, M. Velasco Arribas, M. Vera, M. Vinciana, P. Volny-Anne, A. Voudouri, N. Wasmuth, J.C. Wengenroth, C. Wilkins, E. Young, L. Yurdakul, S. Zafra Espinosa, T. Zuilhof, W. Zuure, F. Advancing Migrant Access to Health Services in Europe (aMASE) study team more...
- Subjects
virus diseases - Abstract
Objective: We aimed to estimate the proportion of postmigration HIV acquisition among HIV-positive migrants in Europe. Design: To reach HIV-positive migrants, we designed a cross-sectional study performed in HIV clinics. Methods: The study was conducted from July 2013 to July 2015 in 57 clinics (nine European countries), targeting individuals over 18 years diagnosed in the preceding 5 years and born abroad. Electronic questionnaires supplemented with clinical data were completed in any of 15 languages. Postmigration HIV acquisition was estimated through Bayesian approaches combining extensive information on migration and patients' characteristics. CD4+ cell counts and HIV-RNA trajectories from seroconversion were estimated by bivariate linear mixed models fitted to natural history data. Postmigration acquisition risk factors were investigated with weighted logistic regression. Results: Of 2009 participants, 46% were MSM and a third originated from sub-Saharan Africa and Latin America & Caribbean, respectively. Median time in host countries was 8 years. Postmigration HIV acquisition was 63% (95% confidence interval: 57-67%); 72% among MSM, 58 and 51% in heterosexual men and women, respectively. Postmigration HIV acquisition was 71% for Latin America and Caribbean migrants and 45% for people from sub-Saharan Africa. Factors associated with postmigration HIV acquisition among heterosexual women and MSM were age at migration, length of stay in host country and HIV diagnosis year and among heterosexual men, length of stay in host country and HIV diagnosis year. Conclusion: A substantial proportion of HIV-positive migrants living in Europe acquired HIV postmigration. This has important implications for European public health policies. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. more...
- Published
- 2017
12. Styles of public asset management in Dutch regional water management
- Author
-
van Buuren, M. W., Bil, J. A., Roovers, G. J., Bakker, Jaap, Frangopol, Dan M., van Breugel, Klaas, and Public Administration
- Abstract
Modern infrastructural asset management within the public domain has to deal with many challenges. It has to deal with more and more uncertainties, climatic as well as socio-economical. Furthermore, demands from politicians and society on the functioning of these assets are growing as well. Bad performance of intensively used networks is less and less tolerated, while available budgets are reduced. Finally, more and more stakeholders have to be taken into account while planning and implementing asset management. Regular asset management focuses on the lifecycle of assets, and puts investments in assets in their life-cycle perspective. It considers the performance of assets within the context of their risks and costs. But as in infrastructure asset management goals often are derived from the public interest, this narrow focus of regular asset management can hamper an integrated and holistic view on public interests. Thus, a broadened integrated focus - from different public interests - is needed to realize the desired (public) values: public asset management. Dutch regional water managers have to deal with these trends, especially when it comes to their contribution to the transition towards sustainable energy. To deal with them they need to extend their regular approach of asset management, focused on exploitation and current functions of assets, to a more broadened, public orientated style of asset management in which opportunities for sustainable energy production are capitalized. Hereto, four styles of public asset management can be discerned, depending on task orientation and strategy: monofunctional, integrated, accommodating and learning asset management. This article answers the question which factors explain the selection of a specific style by Dutch water boards and how this might contribute to adding more public value to the management of their assets. more...
- Published
- 2017
13. The Relevant Markets for Meat Production and Processing in the Czech Republic: Analysis of the Price Movements
- Author
-
Vladimir Hajko and Bil, J.
- Subjects
HB Economic Theory ,jel:L66 ,HG Finance ,HF Commerce ,jel:C32 ,jel:L40 ,Market delineation, meat prices, relevant market, cointegration, causality - Abstract
The objective of this article is to apply empirical methods to delineate the relevant market for various types of meat in the Czech Republic during the period of 2006–2010. This procedure may be useful when there is little availability of micro-data and the complete SSNIP test approach is not feasible, but when the prices can be obtained at an aggregated level. The methods employed ranged from the visual assessment, simple correlation analysis and testing of the law of one price, to the more complex cointegration analysis and testing of Granger causality. The application of the methodology is used both for the geographical delineation and for the product delineation. We reach the following conclusions: For the chicken meat, the market in the Czech Republic can be considered independent both geographically and by product. For the pork meat, the relevant market includes, apart from the Czech Republic, also Germany and Slovakia. The relevant beef meat market includes the Czech Republic and Germany. more...
- Published
- 2013
14. Pre-expositieprofylaxe voor preventie van hiv-transmissie: stand van zaken en Amsterdam PrEP-project
- Author
-
Hoornenborg, E., de Vries, H. J. C., Schim van der Loeff, M. F., Davidovich, U., Bil, J. P., Achterbergh, R. A., Fennema, J. S., Prins, Maria, Graduate School, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Dermatology, Infectious diseases, and General Internal Medicine more...
- Published
- 2015
15. Prevalence of hepatitis B virus and hepatitis C virus infection among six ethnic groups living in Amsterdam, the Netherlands – The HELIUS study
- Author
-
Zuure, F., primary, Bil, J., additional, Visser, M., additional, van Rijckevorsel, G., additional, Snijder, M., additional, Blom, P., additional, Sonder, G., additional, Schinkel, J., additional, and Prins, M., additional more...
- Published
- 2017
- Full Text
- View/download PDF
16. Integrating voluntary hepatitis B, C and HIV screening in the compulsory tuberculosis entry screening for immigrants, The Netherlands: a pilot project
- Author
-
Bil, J., primary, Schrooders, P., additional, Prins, M., additional, Kouw, P., additional, Klomp, J., additional, Scholing, M., additional, Huijbregts, L., additional, Sonder, G., additional, Waegemaekers, T., additional, de Vries, H., additional, Meijer, W., additional, Zuure, F., additional, and Tostmann, A., additional more...
- Published
- 2017
- Full Text
- View/download PDF
17. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
- Author
-
Dwojak, M, primary, Bobrowicz, M, additional, Bil, J, additional, Bojarczuk, K, additional, Pyrzynska, B, additional, Siernicka, M, additional, Malenda, A, additional, Lech-Maranda, E, additional, Tomczak, W, additional, Giannopoulos, K, additional, Golab, J, additional, and Winiarska, M, additional more...
- Published
- 2015
- Full Text
- View/download PDF
18. De lof die leer en leven stempelt. Over orthodoxie als theologisch begrip
- Author
-
van den Brink, G., Bil, J., Boele, A., Geene, B., Faculty of Religion and Theology, and Church History
- Published
- 2008
19. FRI-459 - Prevalence of hepatitis B virus and hepatitis C virus infection among six ethnic groups living in Amsterdam, the Netherlands – The HELIUS study
- Author
-
Zuure, F., Bil, J., Visser, M., van Rijckevorsel, G., Snijder, M., Blom, P., Sonder, G., Schinkel, J., and Prins, M.
- Published
- 2017
- Full Text
- View/download PDF
20. FRI-463 - Integrating voluntary hepatitis B, C and HIV screening in the compulsory tuberculosis entry screening for immigrants, The Netherlands: a pilot project
- Author
-
Bil, J., Schrooders, P., Prins, M., Kouw, P., Klomp, J., Scholing, M., Huijbregts, L., Sonder, G., Waegemaekers, T., de Vries, H., Meijer, W., Zuure, F., and Tostmann, A.
- Published
- 2017
- Full Text
- View/download PDF
21. First in man study of dedicated bifurcation sirolimus eluting stent:complete 6 months clinical results of BiOSS LIM Registry
- Author
-
Gil, R., primary, Vassiliev, D., additional, Bil, J., additional, and Inigo Garcia, L. A., additional
- Published
- 2013
- Full Text
- View/download PDF
22. Regular drug eluting stent versus dedicated bifurcation paclitaxel-eluting stent in coronary bifurcation treatment: interim analysis of randomized POLBOS study
- Author
-
Gil, R. J., primary, Vassilev, D., additional, Bil, J., additional, Kern, A., additional, Formuszewicz, R., additional, and Dobrzycki, S., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Conservative treatment as a therapeutic option for penetrating aortic ulcer of the aortic arch in a patient with bicuspid aortic valve
- Author
-
Możeńska O, Wojewódzki M, Wiligórska D, Wiligórska N, Robert Gil, and Bil J
24. The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk
- Author
-
Kern Adam, Zaleska M, Możeńska O, and Bil J
25. BORTEZOMIB MODULATES SURFACE CD20 IN B-CELL MALIGNANCIES AND AFFECTS RITUXIMAB-MEDIATED COMPLEMENT-DEPENDENT CYTOTOXICITY
- Author
-
Winiarska, M., Bil, J., Kamil Bojarczuk, Nowis, D., and Golab, J.
26. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice
- Author
-
Jozkowicz Alicja, Was Halina, Issat Tadeusz, Salwa Pawel, Szokalska Angelika, Bil Jacek, Winiarska Magdalena, Bugajski Marek, Nowis Dominika, Dulak Jozef, Stoklosa Tomasz, and Golab Jakub
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background HO-1 participates in the degradation of heme. Its products can exert unique cytoprotective effects. Numerous tumors express high levels of HO-1 indicating that this enzyme might be a potential therapeutic target. In this study we decided to evaluate potential cytostatic/cytotoxic effects of zinc protoporphyrin IX (Zn(II)PPIX), a selective HO-1 inhibitor and to evaluate its antitumor activity in combination with chemotherapeutics. Methods Cytostatic/cytotoxic effects of Zn(II)PPIX were evaluated with crystal violet staining and clonogenic assay. Western blotting was used for the evaluation of protein expression. Flow cytometry was used to evaluate the influence of Zn(II)PPIX on the induction of apoptosis and generation of reactive oxygen species. Knock-down of HO-1 expression was achieved with siRNA. Antitumor effects of Zn(II)PPIX alone or in combination with chemotherapeutics were measured in transplantation tumor models. Results Zn(II)PPIX induced significant accumulation of reactive oxygen species in tumor cells. This effect was partly reversed by administration of exogenous bilirubin. Moreover, Zn(II)PPIX exerted potent cytostatic/cytotoxic effects against human and murine tumor cell lines. Despite a significant time and dose-dependent decrease in cyclin D expression in Zn(II)PPIX-treated cells no accumulation of tumor cells in G1 phase of the cell cycle was observed. However, incubation of C-26 cells with Zn(II)PPIX increased the percentage of cells in sub-G1 phase of the cells cycle. Flow cytometry studies with propidium iodide and annexin V staining as well as detection of cleaved caspase 3 by Western blotting revealed that Zn(II)PPIX can induce apoptosis of tumor cells. B16F10 melanoma cells overexpressing HO-1 and transplanted into syngeneic mice were resistant to either Zn(II)PPIX or antitumor effects of cisplatin. Zn(II)PPIX was unable to potentiate antitumor effects of 5-fluorouracil, cisplatin or doxorubicin in three different tumor models, but significantly potentiated toxicity of 5-FU and cisplatin. Conclusion Inhibition of HO-1 exerts antitumor effects but should not be used to potentiate antitumor effects of cancer chemotherapeutics unless procedures of selective tumor targeting of HO-1 inhibitors are developed. more...
- Published
- 2008
- Full Text
- View/download PDF
27. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
- Author
-
Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, and Wasik M more...
- Abstract
Background: Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymphoma effects. The objective of this study was to evaluate the influence of statins on rituximab-induced killing of B cell lymphomas.Methods and Findings: Complement-dependent cytotoxicity (CDC) was assessed by MTT and Alamar blue assays as well as trypan blue staining, and antibody-dependent cellular cytotoxicity (ADCC) was assessed by a 51Cr release assay. Statins were found to significantly decrease rituximab-mediated CDC and ADCC of B cell lymphoma cells. Incubation of B cell lymphoma cells with statins decreased CD20 immunostaining in flow cytometry studies but did not affect total cellular levels of CD20 as measured with RT-PCR and Western blotting. Similar effects are exerted by other cholesterol-depleting agents (methyl-beta-cyclodextrin and berberine), but not filipin III, indicating that the presence of plasma membrane cholesterol and not lipid rafts is required for rituximab-mediated CDC. Immunofluorescence microscopy using double staining with monoclonal antibodies (mAbs) directed against a conformational epitope and a linear cytoplasmic epitope revealed that CD20 is present in the plasma membrane in comparable amounts in control and statin-treated cells. Atomic force microscopy and limited proteolysis indicated that statins, through cholesterol depletion, induce conformational changes in CD20 that result in impaired binding of anti-CD20 mAb. An in vivo reduction of cholesterol induced by short-term treatment of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20 binding to freshly isolated B cells.Conclusions: Statins were shown to interfere with both detection of CD20 and antilymphoma activity of rituximab. These studies have significant clinical implications, as impaired binding of mAbs to conformational epitopes of CD20 elicited by statins could delay diagnosis, postpone effective treatment, or impair anti-lymphoma activity of rituximab. [ABSTRACT FROM AUTHOR] more...- Published
- 2008
- Full Text
- View/download PDF
28. Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial)
- Author
-
Marianne Brodmann, Stanislaw Bartus, Laura Schneller, Robert J. Gil, Fabio Mangiacapra, Viktor Óriás, Gabor G. Toth, Emanuele Barbato, Jacek Bil, Zoltán Ruzsa, Toth, G., Brodmann, M., Barbato, E., Mangiacapra, F., Schneller, L., Orias, V., Gil, R., Bil, J., Bartus, S., and Ruzsa, Z. more...
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Ischemia ,Coronary Artery Disease ,Fractional flow reserve ,030204 cardiovascular system & hematology ,Conservative Treatment ,Revascularization ,Coronary artery disease ,Peripheral Arterial Disease ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Internal medicine ,Catheterization, Peripheral ,medicine ,Humans ,Multicenter Studies as Topic ,030212 general & internal medicine ,Myocardial infarction ,Randomized Controlled Trials as Topic ,Leg ,business.industry ,Percutaneous coronary intervention ,Critical limb ischemia ,medicine.disease ,Fractional Flow Reserve, Myocardial ,Clinical trial ,Early Diagnosis ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Critical limb ischemia is associated with excessively high risk for cardiovascular events, including myocardial infarction and death. Additionally, in this patient population non-invasive evaluation of coronary artery disease is limited due to (1) inability of exercise testing, (2) frequent occurrence of balanced ischemia and (3) frequent occurrence of diffuse coronary calcification. Intentional Coronary Revascularization Versus Conservative Therapy in Patients Undergoing Peripheral Artery Revascularization Due to Critical Limb Ischemia trial (INCORPORATE trial) is a multicentric international randomized open label clinical trial. Trial will recruit patients, who underwent successful peripheral artery revascularization due to critical limb ischemia and randomize 1:1 to conservative medical therapy versus an immediate invasive strategy to investigate and treat coronary artery disease. The objective is to evaluate whether intentional invasive strategy with ischemia targeted reasonably complete coronary revascularization is superior as compared to conventional primarily conservative approach in terms of spontaneous myocardial infarction and overall survival at 12 months follow-up. The trial is registered at clinicaltrials.gov (NCT03712644). more...
- Published
- 2019
- Full Text
- View/download PDF
29. De lof die leer en leven stempelt. Over orthodoxie als theologisch begrip
- Author
-
Gijsbert van den Brink, Bil, J., Boele, A., and Geene, B.
30. Comparative Ten-Year Outcomes in Chronic and Acute Coronary Syndrome Patients Undergoing Invasive Diagnostics-Insights from the KORONEF Registry.
- Author
-
Kern A, Stompór T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak K, Pawlak D, Poskrobko G, Andrasz E, Gromadziński L, Jalali R, Onichimowski D, Piwko G, Zalewski A, and Bil J
- Abstract
Background: This study aimed to characterize acute coronary syndrome (ACS) patients undergoing invasive diagnostics and to evaluate prognostic factors for all-cause mortality over a 10-year follow-up period., Methods: The KORONEF study was a prospective, observational, single-center study that enrolled 492 patients, of whom 467 had confirmed coronary artery disease (CAD). Baseline demographic, clinical, laboratory, and procedural data were analyzed, focusing on the differences between ACS and chronic coronary syndrome (CCS) patients., Results: Males made up the majority of both the CCS and ACS groups (62.2% vs. 63.6%, p = 0.773), with no statistically significant difference in patient age between the CCS and ACS subpopulations (64.9 ± 9.5 vs. 63.7 ± 10.3, p = 0.106). The 10-year all-cause mortality was 29.8%, with no statistically significant difference between ACS and CCS patients. However, statistically significantly more patients with CCS underwent CABG in the follow-up than ACS patients (9.9% vs. 4.6%, p = 0.042). In a multivariable analysis, in the ACS subgroup, statistically significant predictors of all-cause mortality at 10 years included being between 75 and 90 years old (HR 4.99), not having had a previous stroke (HR 0.27), the absence of cardiac arrest (HR 0.20), and a left ventricular ejection fraction > 60% (HR 0.23)., Conclusions: The long-term outcomes of the ACS patients highlight age and left ventricular function as significant prognostic factors, underscoring the importance of these parameters in risk stratification. more...
- Published
- 2024
- Full Text
- View/download PDF
31. Treatment of in-stent restenosis with ultrathin-strut versus thin-strut drug-eluting stents or drug-eluting balloons: a multicentre registry.
- Author
-
De Filippo O, Wańha W, Sanavia T, Januszek R, Giacobbe F, Campo G, Pinxterhuis TH, Capodanno D, Tomasiewicz B, Iannaccone M, Leone A, Wolny R, Bruno F, Patti G, Musumeci G, Liccardo G, Verardi R, Roubin SR, Tarantini G, Kuźma Ł, Perl L, Gagnor A, Reczuch K, Conrotto F, Tuttolomondo D, Ploumen EH, Niezgoda P, Caglioni S, Omedè P, Greco A, Kubica J, Gil RJ, Piccolo R, Kornowski R, Bil J, Morena A, Zocca P, Pennone M, Gąsior M, Jaguszewski M, von Birgelen C, Fariselli P, De Ferrari GM, Wojakowski W, and D'Ascenzo F more...
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention adverse effects, Angioplasty, Balloon, Coronary instrumentation, Angioplasty, Balloon, Coronary adverse effects, Coronary Artery Disease therapy, Coronary Artery Disease diagnostic imaging, Prosthesis Design, Drug-Eluting Stents, Coronary Restenosis, Registries
- Abstract
Background: Limited data exist on ultrathin-strut drug-eluting stent (ultrathin DES) performance in DES in-stent restenosis (ISR)., Aims: We aimed to assess the efficacy and safety of ultrathin DES compared to thin-strut DES and drug-eluting balloons (DEB) for DES-ISR., Methods: Patients from the DEB Dragon (ClinicalTrials.gov: NCT04415216) and ULTRA registries (ClinicalTrials.gov: NCT05205148) were divided into ultrathin DES, thin-strut DES, or DEB groups for DES-ISR treatment. Both propensity score matching (PSM) and inverse probability weighting (IPW) were considered to adjust the distribution of patients in each class. Cox regression was applied to the following main endpoints: device-oriented composite endpoints (DOCE; including cardiac death, target lesion revascularisation [TLR] and target vessel myocardial infarction), TLR and target vessel revascularisation (TVR)., Results: A total of 269, 541, and 557 patients received an ultrathin DES, thin-strut DES, and DEB, respectively. After 3 years of follow-up, in the IPW-adjusted overall cohort, ultrathin DES were associated with a significantly reduced risk of DOCE compared to DEBs (hazard ratio [HR] 0.353, 95% confidence interval [CI]: 0.194-0.642; p<0.001), as well as thin-strut DES (HR 0.645, 95% CI: 0.457-0.911; p=0.013). Compared to DEBs, ultrathin DES also reduced the risks of both TLR (HR 0.184, 95% CI: 0.081-0.417; p<0.001) and TVR (HR 0.188, 95% CI: 0.093-0.379; p<0.001), while thin-strut DES did not (TLR: HR 0.686, 95% CI: 0.407-1.157; p=0.157; TVR: HR 0.706, 95% CI: 0.453-1.101; p=0.124). For diffuse ISR patients, ultrathin DES reduced the risk of DOCE (HR 0.364, 95% CI: 0.188-0.705; p=0.003), as did thin-strut DES (HR 0.602, 95% CI: 0.367-0.987; p=0.044), while a reduction of TLR (HR 0.220, 95% CI: 0.091-0.531; p<0.001) and TVR (HR 0.241, 95% CI: 0.113-0.513; p<0.001) was achieved only by ultrathin DES., Conclusions: Ultrathin DES were associated with reduced DOCE, TLR and TVR risks in diffuse ISR compared to DEBs. more...
- Published
- 2024
- Full Text
- View/download PDF
32. Soluble Urokinase Plasminogen Activator Receptor as a Predictor of All-Cause Death in Patients Undergoing Coronary Angiography at 10-Year Follow-Up.
- Author
-
Kern A, Stompór T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak K, Pawlak D, Poskrobko G, Andrasz E, Gromadziński L, Jalali R, Onichimowski D, Piwko G, Zalewski A, and Bil J
- Abstract
Background: We aimed to explore the predictive role of soluble urokinase plasminogen activator receptor (suPAR) in patients undergoing coronary angiography by systematically evaluating its association with adverse cardiovascular events at 10 years follow-up. Methods: The KORONEF study was a single-center, observational, prospective study with 492 subjects included. In the multivariable Cox regression model, we checked the impact of suPAR, neutrophil elastase, myeloperoxidase, and DNase 1 on long-term outcomes. Results: The mean study population age was 64.4 ± 9.9 years, and there were 37.2% women. We divided the population into tertiles of suPAR levels (T1 0.793-2.135 ng/mL; T2 2.136-2.868 ng/mL; and T3 2.872-8.677 ng/mL). Patients with higher suPAR concentrations were more often females (tertile 1 vs. tertile 3: 27.4% vs. 50.6%, p < 0.001) and older age (60.8 ± 8.7 years vs. 68.8 ± 9.5 years, p < 0.001). They also characterized higher incidence of diabetes (17.7% vs. 38.0%, p < 0.001), previous myocardial infarction (22% vs. 44.8%, p < 0.001), and chronic kidney disease (3% vs. 18.4%, p < 0.001), but lower incidence of dyslipidemia (54.3% vs. 35.6%). The 10-year all-cause death rates were 14.6% vs. 34.1%, HR 2.68, 95% CI 1.66-4.33, p < 0.001 for tertile 2, and 14.6% vs. 39.9%, HR 3.24, 95% CI 2.03-5.17, p < 0.001 for tertile 3. The optimal cut-off suPAR value of 2.39 ng/mL provided a sensitivity of 66.9% and a specificity of 54.6% in predicting all-cause death. Conclusions: The association of elevated suPAR with increased mortality risk suggests its potential relevance in predicting long-term outcomes and may help inform more individualized management strategies for high-risk patients. more...
- Published
- 2024
- Full Text
- View/download PDF
33. Drug-Eluting Balloons and Drug-Eluting Stents in Diabetic Patients Undergoing Percutaneous Coronary Intervention Due to Restenosis-DM-Dragon Registry.
- Author
-
Niezgoda P, Kasprzak M, Kubica J, Kuźma Ł, Januszek R, Iwańczyk S, Tomasiewicz B, Bil J, Kowalewski M, Jaguszewski M, Wybraniec M, Reczuch K, Dobrzycki S, Bartuś S, Lesiak M, Gąsior M, Wolny R, Witkowski A, Gil R, Cortese B, D'Ascenzo F, Wojakowski W, and Wańha W more...
- Abstract
Background : The rate of in-stent restenosis (ISR) is decreasing; however, it is still a challenge for contemporary invasive cardiologists. Therapeutic methods, including drug-eluting balloons (DEBs), intravascular lithotripsy, excimer laser coronary atherectomy, and imaging-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES), have been implemented. Patients with diabetes mellitus (DM) are burdened with a higher risk of ISR than the general population. Aims : DM-Dragon is aimed at evaluating the clinical outcomes of ISR treatment with DEBs vs. DES, focusing on patients with co-existing diabetes mellitus. Methods : The DM-Dragon registry is a retrospective study comprising data from nine high-volume PCI centers in Poland. A total of 1117 patients, of whom 473 individuals had DM and were treated with PCI due to ISR, were included. After propensity-score matching (PSM), 198 pairs were created for further analysis. The primary outcome of the study was target lesion revascularization (TLR). Results : In DM patients after PSM, TLR occurred in 21 (10.61%) vs. 20 (10.1%) in non-diabetic patients, p = 0.8690. Rates of target vessel revascularization (TVR), target vessel myocardial infarction, device-oriented composite endpoint (DOCE), and cardiac death did not differ significantly. Among diabetic patients, the risk of all-cause mortality was significantly lower in the DEB group (2.78% vs. 11.11%, HR 3.67 (95% confidence interval, CI) [1.01-13.3), p = 0.0483). Conclusions : PCI with DEBs is almost as effective as DES implantation in DM patients treated for ISR. In DM-Dragon, the rate of all-cause death was significantly lower in patients treated with DEBs. Further large-scale, randomized clinical trials would be needed to support these findings. more...
- Published
- 2024
- Full Text
- View/download PDF
34. Correction: Intentional coronary revascularization versus conservative therapy in patients after peripheral artery revascularization due to critical limb ischemia: the INCORPORATE trial.
- Author
-
Toth GG, Brodmann M, Kanoun Schnur SS, Bartus S, Vrsalovic M, Krestianinov O, Kala P, Bil J, Gil R, Kanovsky J, Di Serafino L, Paolucci L, Barbato E, Mangiacapra F, and Ruzsa Z
- Published
- 2024
- Full Text
- View/download PDF
35. Intentional coronary revascularization versus conservative therapy in patients after peripheral artery revascularization due to critical limb ischemia: the INCORPORATE trial.
- Author
-
Toth GG, Brodmann M, Kanoun Schnur SS, Bartus S, Vrsalovic M, Krestianinov O, Kala P, Bil J, Gil R, Kanovsky J, Di Serafino L, Paolucci L, Barbato E, Mangiacapra F, and Ruzsa Z
- Abstract
Objectives: INCORPORATE trial was designed to evaluate whether default coronary-angiography (CA) and ischemia-targeted revascularization is superior compared to a conservative approach for patients with treated critical limb ischemia (CLI). Registered at clinicaltrials.gov (NCT03712644) on October 19, 2018., Background: Severe peripheral artery disease is associated with increased cardiovascular risk and poor outcomes., Methods: INCORPORATE was an open-label, prospective 1:1 randomized multicentric trial that recruited patients who had undergone successful CLI treatment. Patients were randomized to either a conservative or invasive approach regarding potential coronary artery disease (CAD). The conservative group received optimal medical therapy alone, while the invasive group had routine CA and fractional flow reserve-guided revascularization. The primary endpoint was myocardial infarction (MI) and 12-month mortality., Results: Due to COVID-19 pandemic burdens, recruitment was halted prematurely. One hundred eighty-five patients were enrolled. Baseline cardiac symptoms were scarce with 92% being asymptomatic. Eighty-nine patients were randomized to the invasive approach of whom 73 underwent CA. Thirty-four percent had functional single-vessel disease, 26% had functional multi-vessel disease, and 90% achieved complete revascularization. Conservative and invasive groups had similar incidences of death and MI at 1 year (11% vs 10%; hazard ratio 1.21 [0.49-2.98]). Major adverse cardiac and cerebrovascular events (MACCE) trended for hazard in the Conservative group (20 vs 10%; hazard ratio 1.94 [0.90-4.19]). In the per-protocol analysis, the primary endpoint remained insignificantly different (11% vs 7%; hazard ratio 2.01 [0.72-5.57]), but the conservative approach had a higher MACCE risk (20% vs 7%; hazard ratio 2.88 [1.24-6.68])., Conclusion: This trial found no significant difference in the primary endpoint but observed a trend of higher MACCE in the conservative arm., (© 2024. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
36. Ten-Year Outcomes in Patients Undergoing Simultaneous Coronary and Renal Angiography-Does Renal Artery Stenosis Matter?
- Author
-
Kern A, Stompór T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak D, Poskrobko G, Andrasz E, Gromadziński L, Jalali R, Onichimowski D, Piwko G, Zalewski A, and Bil J
- Abstract
Background: We aimed to characterize the population of consecutive patients undergoing coronary angiography with simultaneous renal artery angiography and assess prognostic factors at a 10 year follow-up. Methods: The KORONEF study was a prospective, single-center, observational, and descriptive study with 492 patients included. We analyzed several baseline demographics, clinical and periprocedural characteristics, and laboratory data, and we assessed the results of coronary angiography and renal artery angiography. Results: The study population consisted of 37.2% women, and the mean age was 64.4 ± 9.9 years (min. 30 years, max. 89 years). Angiography revealed significant renal artery stenosis (RAS) in 35 (7.1%) patients. Among patients with significant RAS (≥50%), we observed more women (57.1% vs. 35.7%, p = 0.011), and patients were older (69.1 ± 10.4 years vs. 64.0 ± 9.7 years, p = 0.005). In the whole population, all-cause death was reported in 29.9% of patients, myocardial infarction (MI) rate-in 11.8%, and stroke-in 4.9%. In the multivariable analysis, independent predictors of death were age 65-75 years (HR 2.88), age > 75 years (HR 8.07), diabetes (HR 1.59), previous MI (HR 1.64), chronic kidney disease (HR 2.22), unstable angina (HR 0.37), and left ventricular ejection fraction > 60% (HR 0.43). Conclusions: Over a 10 year follow-up, the all-cause death rate was 29.9%, showing no statistically significant differences between patients with and without significant RAS. more...
- Published
- 2024
- Full Text
- View/download PDF
37. Percutaneous Coronary Interventions with Sirolimus-Eluting Alex Plus Stents in Patients with or without Diabetes: 4-Year Results.
- Author
-
Bil J, Tyczynski M, Kern A, Bojko K, and Gil RJ
- Abstract
We characterized the performance, as well as the safety, of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), implanted in patients with type 2 diabetes (DM) with a 4-year follow-up. We defined the primary endpoint as the 48-month rate of major cardiovascular adverse events (MACE), including cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). The secondary endpoints were all-cause death, cardiac death, MI, and TLR rates at 12, 24, 36, and 48 months. We enrolled 232 patients in whom 282 stents were implanted, including 97 DM and 135 non-DM patients. The mean age of the DM patients was 69.5 ± 10.1 years and females accounted for 30% of the patients. DM patients had higher rates of arterial hypertension (97% vs. 88%, p = 0.016), dyslipidemia (86% vs. 70%, p = 0.005), prior MI (61% vs. 40%, p = 0.002), prior PCI (65% vs. 50%, p = 0.020), and prior CABG (14% vs. 5.9%, p = 0.029). We recorded statistically significant differences for MACE (HR 1.85, 95% CI 1.01-3.41, p = 0.046), cardiac death (HR 4.46, 95% CI 1.44-13.8, p = 0.010), and MI (HR 3.17, 95% CI 1.10-9.12, p = 0.033), but not for TLR, between DM and non-DM patients in terms of the analyzed endpoints at 4 years. Our study showed that Alex Plus was efficient and safe in a contemporary cohort of real-world DM patients undergoing percutaneous revascularization. more...
- Published
- 2024
- Full Text
- View/download PDF
38. The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.
- Author
-
Gil RJ, Kern A, Bojko K, Gziut-Rudkowska A, Vassilev D, and Bil J
- Abstract
This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary bifurcation. The deployment of a single stent in the main vessel-main branch across a side branch was the default strategy in all patients. The primary endpoint was the rate of major cardiovascular events (cardiac death, myocardial infarction, and target lesion revascularization) at 48 months. We enrolled 230 patients, allocating 116 patients to the BiOSS LIM C group and 114 patients to the rDES group. Most procedures were elective (BiOSS vs. rDES: 48.3% vs. 59.6%, p = 0.09) and performed in bifurcations within the left anterior descending/diagonal branch (BiOSS vs. rDES: 51.7% vs. 61.4%, p = 0.15). At 48 months, there were no statistically significant differences between the BiOSS and rDES groups in terms of major adverse cardiovascular events (MACE), cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR) as follows: MACEs-18.1% vs. 14.9%, HR 1.36, 95% CI 0.62-2.22, and p = 0.33; cardiac death-4.3% vs. 3.5%, HR 1.23, 95% CI 0.33-4.56, and p = 0.75; MI-2.6% vs. 3.5%, HR 0.73, 95% CI 0.17-3.23, and p = 0.68; and TLR-11.2% vs. 7.9%, HR 1.66, 95% CI 0.75-3.71, and p = 0.21. The implantation success rate of the BiOSS LIM C stent was very high, and the cumulative MACE rates were promising. The POLBOS 3 trial sets an important benchmark for treating non-LM coronary bifurcations (ClinicalTrials.gov NCT03548272). more...
- Published
- 2024
- Full Text
- View/download PDF
39. Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke.
- Author
-
Jalali R, Zwiernik J, Rotkiewicz E, Zwiernik B, Kern A, Bil J, Jalali A, Manta J, and Romaszko J
- Abstract
Background: Ischemic stroke is one of the leading causes of mortality and disability. The neuroimaging methods are the gold standard for diagnostics. Biomarkers of cerebral ischemia are considered to be potentially helpful in the determination of the etiology and prognosis of patients with ischemic stroke., Aim: This study aimed to investigate the usefulness of serum S100B protein levels as a short- and long-term prognostic factor in patients with ischemic stroke., Study Design and Methods: The study group comprised 65 patients with ischemic stroke. S100B protein levels were measured by immunoenzymatic assay. Short-term functional outcome was determined by the NIHSS score on day 1 and the difference in the NIHSS scores between day 1 and day 9 (delta NIHSS). Long-term outcome was assessed by the modified Rankin Scale (MRS) at 3 months after the stroke. At the end of the study, patients were divided into groups based on the NIHSS score on day 9 (0-8 "good" and >8 "poor"), the delta NIHSS ("no improvement" ≤0 and >0 "improvement"), and the MRS ("good" 0-2 and >2 "poor"). Differences in S100B levels between groups were analyzed with the ROC curve to establish the optimal cut-off point for S100B. The odds ratio was calculated to determine the strength of association. Correlations between S100B levels at three time points and these variables were evaluated., Results: We revealed a statistically significant correlation between S100B levels at each measurement point (<24 h, 24-48 H, 48-72 h) and the NIHSS score on day 9 (R Spearman 0.534, 0.631, and 0.517, respectively) and the MRS score after 3 months (R Spearman 0.620, 0.657, and 0.617, respectively). No statistically significant correlation was found between S100B levels and the delta NIHSS. Analysis of the ROC curve confirmed a high sensitivity and specificity for S100B. The calculated AUC for the NIHSS on day 9 were 90.2%, 95.0%, and 82.2%, respectively, and for the MRS, 83.5%, 83.4%, and 84.0%, respectively. After determining the S100B cut-off, the odds ratio for beneficial effect (NIHSS ≤ 8 at day 9 or MRS 0-2 after 3 months) was determined for each sampling point., Conclusion: S100B is a useful marker for predicting short- and long-term functional outcomes in patients with ischemic stroke. more...
- Published
- 2024
- Full Text
- View/download PDF
40. Clinical characteristics and predictors of in-hospital mortality of patients hospitalized with myocardial infarction before and during COVID-19 pandemic.
- Author
-
Kern A, Pawlak S, Poskrobko G, Bojko K, Gromadziński L, Onichimowski D, Jalali R, Andrasz E, and Bil J
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Retrospective Studies, Risk Factors, Myocardial Infarction mortality, Myocardial Infarction therapy, Myocardial Infarction diagnosis, SARS-CoV-2, Hospitalization statistics & numerical data, Pandemics, COVID-19 mortality, COVID-19 epidemiology, Hospital Mortality trends
- Abstract
Background: The COVID-19 pandemic has impacted many acute coronary syndrome (ACS) care aspects. The aim was to compare the patient profile, ACS characteristics, and the outcomes in patients referred to the invasive cardiology department before (March 2019 - February 2020) and during the COVID-19 pandemic (March 2020 - February 2021)., Methods: Clinical and demographic features, comorbidities, laboratory parameters at admission, and periprocedural data were recorded. The relationship of these parameters with in-hospital mortality was assessed., Results: Before the COVID-19 pandemic, 664 patients were admitted due to ACS (mean age 67.16 ± 11.94 years, females 32.1%), and during the COVID-19 pandemic 545 ACS patients were recorded [mean age 66.02 ± 12.02 years (p = 0.463), females 31% (p = 0.706)]. A 17.8% decrease in the ACS rate was observed. During the pandemic, there were more STEMI patients (44.3% vs. 52.1%, p < 0.001) and fewer patients treated conservatively (24.9% vs. 8%, p < 0.001). Most lesions were located in the left anterior descending artery (53.4% vs. 54.7%), but post-percutaneous coronary intervention TIMI 3 was observed more frequently before the pandemic (83.9% vs. 75.1%, p < 0.001). Periprocedural complication rates did not differ between the groups. In-hospital outcomes did not differ between analyzed periods regarding all-cause death nor cardiac death rates, 5.3% vs. 4.6% (p = 0.598) and 4.5% vs. 3.7% (p = 0.473), respectively., Conclusions: Based on the analysis of 1209 patients, a decrease in ACS patients admitted during the pandemic was recorded, but in-hospital mortality remained similar. more...
- Published
- 2024
- Full Text
- View/download PDF
41. Oral anticoagulation therapy in atrial fibrillation patients at high risk of bleeding: Clinical characteristics and treatment strategies based on data from the Polish multicenter register of atrial fibrillation (POL-AF).
- Author
-
Maciorowska M, Uziębło-Życzkowska B, Gorczyca-Głowacka I, Wożakowska-Kapłon B, Jelonek O, Wójcik M, Błaszczyk R, Kapłon-Cieślicka A, Gawałko M, Tokarek T, Rajtar-Salwa R, Bil J, Wojewódzki M, Szpotowicz A, Krzciuk M, Bednarski J, Bakuła-Ostalska E, Tomaszuk-Kazberuk A, Szyszkowska A, Wełnicki M, Mamcarz A, and Krzesiński P more...
- Subjects
- Aged, Female, Humans, Male, Administration, Oral, Anticoagulants adverse effects, Creatinine, Gastrointestinal Hemorrhage chemically induced, Gastrointestinal Hemorrhage complications, Gastrointestinal Hemorrhage drug therapy, Poland, Risk Factors, Aged, 80 and over, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Stroke drug therapy, Stroke etiology, Stroke prevention & control
- Abstract
Background: Despite its benefits, oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF) is associated with hemorrhagic complications., Aims: We aimed to evaluate clinical characteristics of AF patients at high risk of bleeding and the frequency of OAC use as well as identify factors that predict nonuse of OACs in these patients., Methods: Consecutive AF patients hospitalized for urgent or planned reasons in cardiac centers were prospectively included in the registry in 2019. Patients with HAS-BLED ≥3 (high HAS-BLED group) were assumed to have a high risk of bleeding., Results: Among 3598 patients enrolled in the study, 29.2% were at high risk of bleeding (44.7% female; median [Q1-Q3] age 72 [65-81], CHA2DS2-VASc score 5 [4-6], HAS-BLED 3 [3-4]). In this group, 14.5% of patients did not receive OACs, 68% received NOACs, and 17.5% VKAs. In multivariable analysis, the independent predictors of nonuse of oral OACs were as follows: creatinine level (odds ratio [OR], 1.441; 95% confidence interval [CI], 1.174-1.768; P <0.001), a history of gastrointestinal bleeding (OR, 2.918; 95% CI, 1.395-6.103; P = 0.004), malignant neoplasm (OR, 3.127; 95% CI, 1.332-7.343; P = 0.009), and a history of strokes or transient ischemic attacks (OR, 0.327; 95% CI, 0.166-0.642; P = 0.001)., Conclusions: OACs were used much less frequently in the group with a high HAS-BLED score than in the group with a low score. Independent predictors of nonuse of OACs were creatinine levels, a history of gastrointestinal bleeding, and malignant neoplasms. A history of stroke or transient ischemic attack increased the chances of receiving therapy. more...
- Published
- 2024
- Full Text
- View/download PDF
42. Significance of S100B Protein as a Rapid Diagnostic Tool in Emergency Departments for Traumatic Brain Injury Patients.
- Author
-
Jalali R, Godlewska I, Fadrowska-Szleper M, Pypkowska A, Kern A, Bil J, Manta J, and Romaszko J
- Abstract
Traumatic brain injuries (TBIs) are not only the leading cause of death among people below 44 years of age, but also one of the biggest diagnostic challenges in the emergency set up. We believe that the use of serum biomarkers in diagnosis can help to improve patient care in TBI. One of them is the S100B protein, which is currently proposed as a promising diagnostic tool for TBI and its consequences. In our study, we analyzed serum biomarker S100B in 136 patients admitted to the Emergency Department of the Regional Specialist Hospital in Olsztyn. Participants were divided into three groups: patients with head trauma and alcohol intoxication, patients with head trauma with no alcohol intoxication and a control group of patients with no trauma or with injury in locations other than the head. In our study, as compared to the control group, patients with TBI had a significantly higher S100B level (both with and without intoxication). Moreover, in both groups, the mean S100B protein level was significantly higher in patients with pathological changes in CT. According to our study results, the S100B protein is a promising diagnostic tool, and we propose including its evaluation in routine regimens in patients with TBI. more...
- Published
- 2023
- Full Text
- View/download PDF
43. Statins and Cancer: A Complex Relationship Worth Exploring.
- Author
-
Bil J
- Abstract
This Special Issue, entitled "Statins and Cancer", aims to demonstrate recent and new advances and future trends in using statins in the field of oncology [...].
- Published
- 2023
- Full Text
- View/download PDF
44. 48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent.
- Author
-
Tyczynski M, Kern A, Buller P, Gil RJ, and Bil J
- Abstract
We characterized the performance as well as safety of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), deployed in the acute coronary syndrome (ACS) setting. We enrolled patients who were subjected to percutaneous coronary intervention (PCI) between July 2015 and March 2016 and took into consideration demographics, clinical and laboratory data, and clinical outcomes. We defined the primary endpoint as the 48-month rate of major cardiovascular adverse events (MACE), including cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). The secondary endpoints were all-cause death, cardiac death, MI, and TLR rates at 12-, 24-, 36-, and 48 months. We enrolled 232 patients in whom 282 stents were implanted, including 88 ACS and 144 chronic coronary syndrome (CCS) patients. The mean age of the ACS population was 67 ± 13 years old, and 32% of it consisted of females. Patients with ACS were characterized by lower rates of arterial hypertension (85.2% vs. 95.8%, p = 0.004), dyslipidemia (67% vs. 81.9%, p = 0.01), prior MI (34.1% vs. 57.6%, p < 0.001), and prior PCI (35.2% vs. 68.8%, p < 0.001). At 48 months, among the ACS patients, the rates of MACE, death, cardiac death, MI, and TLR were 23.9%, 11.4%, 7.9%, 9.1% , and 10.2%, respectively. No stent thrombosis cases were reported. Multivariable Cox regression revealed that the statistically significant MACE predictors were massive calcifications in coronary arteries (HR 9.0, 95% CI 1.75-46.3, p = 0.009), post-dilatation (HR 3.78, 95% CI 1.28-11.2, p = 0.016), prior CABG (HR 6.64, 95% CI 1.62-27.1, p = 0.008), vitamin K antagonist use (HR 5.99, 95% CI 1.29-27.8, p = 0.022), and rivaroxaban use (HR 51.7, 95% CI 4.48-596, p = 0.002). The study findings show that Alex Plus was effective and safe in a contemporary cohort of real-world ACS patients undergoing primary PCI. The outcomes were comparable between the ACS and chronic coronary syndrome patients, with a trend of lower TLR in ACS patients at 4 years. more...
- Published
- 2023
- Full Text
- View/download PDF
45. Clinical Outcomes and Prognostic Factors in Complex, High-Risk Indicated Procedure (CHIP) and High-Bleeding-Risk (HBR) Patients Undergoing Percutaneous Coronary Intervention with Sirolimus-Eluting Stent Implantation: 4-Year Results.
- Author
-
Tyczyński M, Kern A, Buller P, Wańha W, Gil RJ, and Bil J
- Abstract
We aimed to characterize the performance and safety of percutaneous coronary intervention (PCI) in complex, high-risk indicated procedure (CHIP) and high-bleeding-risk (HBR) patients at a 4-year follow up. We included all consecutive patients who underwent PCI with the sirolimus-eluting coronary stent Alex Plus (Balton, Poland) between July 2015 and March 2016. We analyzed various baseline demographic and clinical characteristics, laboratory data, and clinical outcomes. We enrolled 232 patients in whom 282 stents were implanted, including 81 patients meeting the CHIP criteria and 76 patients meeting the HBR criteria. In the whole population, the mean age was 68 ± 11 years, and 23.7% were females. Most procedures were performed from radial access (83.2%) using a 6F guiding catheter (95.7%). The lesions were mostly predilated (61.6%), and postdilatation was performed in 37.9%. The device success was 99.6% (in one case, a second stent was required due to heavy calcifications). Additional stents were deployed in 39% of cases due to edge dissection (6.9%), side branch stenting (5.2%), or diffuse disease (26.9%). Myocardial infarction (MI) type 4a was revealed in 2.2% of cases. At 4 years, the MACE rates for the whole population and for CHIP and HBR patients were 23.3%, 29.6%, and 27.6%, respectively. CHIP patients had a higher risk of MACEs (29.6% vs. 19.9%, HR 1.69, p = 0.032) and cardiac death (11.1% vs. 4.6%, HR 2.50, p = 0.048). There were no differences for MI (7.4% vs. 6.6%, p = 0.826) and TLR (18.5% vs. 12.6%, p = 0.150). HBR patients were also characterized by a higher risk of MACEs (27.6% vs. 21.2%, HR 1.84, p = 0.049) and cardiac death (17.1% vs. 1.9%, HR 9.61, p < 0.001). There were no differences for MI (7.9% vs. 6.4%, p = 0.669) and TLR (11.8% vs. 16.0%, p = 0.991). PCI in CHIP and HBR patients is feasible with a low rate of periprocedural complications. Nevertheless, CHIP and HBR patients are at a high risk of future adverse events and require strict surveillance to improve outcomes., Competing Interests: The authors declare no conflict of interest. more...
- Published
- 2023
- Full Text
- View/download PDF
46. Clinical characteristics and 12-month outcomes of patients with myocardial infarction with nonobstructive coronary arteries before and during the COVID-19 pandemic.
- Author
-
Bil J, Kern A, Bujak K, Gierlotka M, Legutko J, Gąsior M, Wańha W, Gromadziński L, and Gil RJ
- Subjects
- Humans, MINOCA, Pandemics, Retrospective Studies, Coronary Angiography, SARS-CoV-2, COVID-19 complications, Myocardial Infarction epidemiology, Stroke
- Abstract
Introduction: SARS‑CoV‑2 infection is associated with an increased risk of thromboembolic complications. Thromboembolism is one of the possible causes of myocardial infarction with nonobstructive coronary arteries (MINOCA)., Objectives: We aimed to compare the characteristics and 12‑month clinical outcomes of patients with MINOCA treated before and during the COVID‑19 pandemic., Patients and Methods: We retrospectively analyzed data of 51 734 patients with acute myocardial infarction registered in the nationwide Polish Registry of Acute Coronary Syndromes database in 2019 and 2020. The final study group included 3178 patients with MINOCA. We compared the baseline characteristics, management strategies, and 12‑month clinical outcomes of the MINOCA patients treated before (2019) and during the COVID‑19 pandemic (2020)., Results: The rate of MINOCA was higher in 2019 than in 2020 (6.3% vs 5.9%; P = 0.03). The only difference between the groups was a higher hypercholesterolemia rate before the pandemic (33.9% vs 28.2%; P <0.001). In‑hospital stroke was observed more frequently during the pandemic (0% vs 0.3%; P = 0.01), whereas other in‑hospital complications were similar between the groups. Most patients were discharged on aspirin (85.6%), a β‑blocker (73.1%), an angiotensin‑converting enzyme inhibitor / angiotensin receptor blocker (70.2%), and a statin (62.7%), but only 50.6% of the participants received a P2Y12 inhibitor. There was no difference in 12‑month all‑cause mortality between the patients with MINOCA treated before and during the pandemic (9.2% vs 11%; P = 0.09)., Conclusions: We observed a lower percentage of MINOCA cases and higher in‑hospital stroke rates in the MINOCA patients treated during the COVID‑19 pandemic (2020). The possible association between worse clinical outcomes of the MINOCA patients treated during the pandemic and the increased risk for thromboembolic complications of SARS‑CoV‑2 infection needs further evaluation. more...
- Published
- 2023
- Full Text
- View/download PDF
47. The Comparison of Predicting Factors and Outcomes of MINOCA and STEMI Patients in the 5-Year Follow-Up.
- Author
-
Buller P, Kern A, Tyczyński M, Rosiak W, Figatowski W, Gil RJ, and Bil J
- Abstract
The long-term outcomes of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) are still not well known. This study aimed to compare the characteristics and outcomes between MINOCA and STEMI patients in a 5-year follow-up. Between 2010 and 2015 we identified 3171 coronary angiography procedures performed due to acute coronary syndrome, from which 153 had a working MINOCA diagnosis, and the final diagnosis of MINOCA was ascribed to 112 (5.8%) patients. Additionally, we matched 166 patients with STEMI and obstructive coronary arteries as the reference group. In MINOCA patients (mean age of 63 years), there were more females (60% vs. 26%, p < 0.001), and patients presented most frequently with NSTEMI (83.9%). Patients with MINOCA had more frequent atrial fibrillation (22% vs. 5.4%, p < 0.001) and higher left ventricular ejection fraction (59 ± 10% vs. 54 ± 10%, p < 0.001) compared to STEMI patients. We observed only a trend for a higher rate of MACE in STEMI patients at 5 years (11.6% vs. 18.7%, HR 1.82, 95% CI 0.91-3.63, p = 0.09). In multivariable Cox regression, only beta-blocker use was a protective factor (a trend observed), with HR 0.33, 95% CI 0.10-1.15, p = 0.082 of future MACE. The outcomes of MINOCA and STEMI patients were comparable in the 5-year follow-up. more...
- Published
- 2023
- Full Text
- View/download PDF
48. Myocardial infarction and ischemic stroke as thrombotic complications in a patient with COVID-19 pneumonia.
- Author
-
Gziut-Rudkowska A, Gil RJ, and Bil J
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
49. When an interventional cardiologist needs to be a vascular surgeon: Successful management of coronary stent loss in a nonagenarian.
- Author
-
Kern A, Godlewski T, Gil R, Bojko K, Pawlak S, Poskrobko G, Andrasz E, and Bil J
- Subjects
- Aged, 80 and over, Humans, Nonagenarians, Stents, Cardiologists, Coronary Artery Disease, Surgeons
- Published
- 2023
- Full Text
- View/download PDF
50. Acute Complications in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries: A Systematic Review with Special Focus on Mechanical Complications.
- Author
-
Bil J, Buller P, Gil RJ, Gromadziński L, Onichimowski D, Jalali R, and Kern A
- Abstract
Background: Recently, we have observed an increasing focus on myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) patients. MINOCA incidence is estimated to be within the range of 5-15% of all MI cases. Unfortunately, MINOCA relates to various conditions that are not rarely hard to identify, including coronary microcirculation dysfunction, epicardial coronary spasm, or plaque erosion. Our systematic review aimed to identify and appraise previous studies which characterized acute complications, with particular focus on mechanical complications, in patients with MINOCA., Methods: Applying the MeSH strategy in PubMed and Embase, two operators independently and systematically reviewed published studies on patients diagnosed with MINOCA and in whom acute complications were described. Papers published in the last 10 years (June 2012-June 2022) to reflect the introduction of the MINOCA definition as well as the current clinical practice were analyzed. The research was conducted in July 2022., Results: The search yielded 192 records. After abstract review, 79 papers were left, and after full-text analysis, we finally included 20 studies. Among 20 studies, there were: one randomized controlled trial, one prospective study, five retrospective studies, 1 case series, and 12 case reports with a total number of 337,385 patients. In the identified literature, we revealed 7 cases of intraventricular septal rupture, 3 cases of free wall rupture with pericardial effusion or cardiac tamponade, and 3 cases of bleeding complications (intracerebral or intestinal bleeding). Moreover, the ventricular arrhythmia incidence ranged from 2% to 13.8%, and the in-hospital death rate ranged from 0.9% to 6.4%., Conclusions: These findings suggest that MINOCA patients should be treated as standard MI patients with watchful monitoring, especially in the first few days., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2022 The Author(s). Published by IMR Press.) more...
- Published
- 2022
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.